Corona

W.H.O Novel Coronavirus(2019-nCoV) Situation Report

Novel Coronavirus(2019-nCoV) Situation Report – 13

Data as reported by 2 February 2020*

YOU MIGHT LIKE

Figure 1. Countries, territories or areas with reported confirmed cases of 2019-nCoV, 2 February 2020

See the actual REPORT HERE

Or scroll to read more

HIGHLIGHTS

  • No new countries have reported cases of 2019-nCoV acute respiratory disease in the last 24 hours.
  • WHO is receiving information about cases from a number of countries. As additional details become known, WHO requests countries to share information in a timely manner as specified in the guidance on Global Surveillance for human infection with novel coronavirus (2019-nCoV).
  • The first death has been reported outside of China, in the Philippines. The patient was a close contact of the first patient confirmed in the Philippines.
  • Due to the high demand for timely and trustworthy information about 2019- nCoV WHO technical risk communication and social media teams have been working closely to track and respond to myths and rumours.

Figure 1. Countries, territories or areas with reported confirmed cases of 2019-nCoV, 2 February 2020

HIGHLIGHTS

  • No new countries have reported cases of 2019-nCoV acute respiratory disease in the last 24 hours.
  • WHO is receiving information about cases from a number of countries. As additional details become known, WHO requests countries to share information in a timely manner as specified in the guidance on Global Surveillance for human infection with novel coronavirus (2019-nCoV).
  • The first death has been reported outside of China, in the Philippines. The patient was a close contact of the first patient confirmed in the Philippines.
  • Due to the high demand for timely and trustworthy information about 2019- nCoV WHO technical risk communication and social media teams have been working closely to track and respond to myths and rumours.

SITUATION IN NUMBERS total and new cases in last 24 hours

Globally

14557 confirmed (2604 new)

China

14411 confirmed (2590 new) 2110 severe (315 new)

304 deaths (45 new)

Outside of China

146 confirmed (14 new) 23 countries

1 death

WHO RISK ASSESSMENT

China Regional Level Global Level

Very High High
High

*The situation report includes information reported to WHO Geneva by 10 AM

CET

TECHNICAL FOCUS: Risk communication and community engagement

Managing the 2019-nCoV ‘infodemic’

The 2019-nCoV outbreak and response has been accompanied by a massive ‘infodemic’ – an over-abundance of information – some accurate and some not – that makes it hard for people to find trustworthy sources and reliable guidance when they need it.

Due to the high demand for timely and trustworthy information about 2019-nCoV, WHO technical risk communication and social media teams have been working closely to track and respond to myths and rumours. Through its headquarters in Geneva, its six regional offices and its partners, the Organization is working 24 hours a day to identify the most prevalent rumours that can potentially harm the public’s health, such as false prevention measures or cures. These myths are then refuted with evidence-based information. WHO is making public health information and advice on the 2019-nCoV, including myth busters, available on its social media channels (including Weibo, Twitter, Facebook, Instagram, LinkedIn, Pinterest) and website.

Country risk communication and community engagement (RCCE) preparedness and response

Country risk communication and community engagement (RCCE) is a critical public health intervention in all countries. Countries should prepare to communicate rapidly, regularly and transparently with the population. All countries should prepare existing public health communication networks, media and community engagement staff to be ready for a possible case, and for the appropriate response if this happens. Countries should coordinate communications with other response organizations and include the community in response operations. WHO stands ready to coordinate with partners to support countries in their communication and community engagement response.

Ensuring a people-centered response to 2019-nCoV

An expanding group of global response organization such as the United Nations Children’s Fund (UNICEF) and the International Federation of Red Cross and Red Crescent Societies (IFRC) are coordinating efforts with WHO to ensure that biomedical recommendations can be applied at the community level. These organizations are active at the global, regional and country level to ensure that affected populations have a voice and are part of the response. Ensuring that global recommendations and communication are tested, adapted and localized will help countries better control the 2019-nCoV outbreak.

SURVEILLANCE

Table 1. Confirmed cases of 2019-nCoV acute respiratory disease reported by provinces, regions and cities in China, 2 February 2020

Province/Region/City Confirmed Cases

Hubei 9074

Zhejiang 661

Guangdong 604

Henan 493

Hunan 463

Anhui 340

Jiangxi 333

Chongqing 262

Sichuan 236

Jiangsu 231

Shandong 225

Beijing 183

Shanghai 177

Fujian 159

Shaanxi 116

Guangxi 111

Hebei 104

Yunnan 99

Heilongjiang 95

Liaoning 64

Hainan 63

Shanxi 56

Gansu 45

Tianjin 40

Guizhou 38

Ningxia 28

Inner Mongolia 26

Xinjiang 23

Jilin 21

Hong Kong SAR 14

Taipei 10

Qinghai 9

Macau SAR 7

Xizang 1

Total 14411

Table 2. Countries, territories or areas with reported confirmed cases of 2019-nCoV. Data as of 2 February 2020

WHO Regional Office

Country/Territory/Area Confirmed Cases

Western Pacific

China* 14411

Japan 20

Republic of Korea 15

Viet Nam 7

Singapore 18

Australia 12

Malaysia 8

Cambodia 1

Philippines 2

South-East Asia

Thailand 19

Nepal 1

Sri Lanka 1

India 2

Region of the Americas

United States of America 8

Canada 4

European Region

France 6

Finland 1

Germany 8

Italy 2

Russian Federation 2

Spain 1

Sweden 1

United Kingdom 2

Eastern Mediterranean

United Arab Emirates 5

Total Confirmed cases

Total 14557

*Confirmed cases in China include cases confirmed in Hong Kong SAR (14 confirmed cases), Macau SAR (7 confirmed cases) and Taipei (10 confirmed cases).
Note: Case classifications are based on WHO case definitions for 2019-nCoV.

Figure 2: Epidemic curve of 2019-nCoV cases (n=76) identified outside of China, by date of onset of symptoms and travel history, 2 February 2020

Note for figure 2: Of the 146 cases reported outside China, 11 were detected while asymptomatic. For the remaining 135 cases, information on date of onset is available only for the 76 cases presented in the epidemiologic curve.

Figure 3: Epidemic curve of 2019-nCoV cases (n=146) identified outside of China, by date of reporting and travel history, 2 February 2020

STRATEGIC OBJECTIVES

WHO’s strategic objectives for this response are to:

  • Limit human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events, and preventing further international spread from China*;
  • Identify, isolate and care for patients early, including providing optimized care for infected patients;
  • Identify and reduce transmission from the animal source;
  • Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment

    options, and accelerate the development of diagnostics, therapeutics and vaccines;

  • Communicate critical risk and event information to all communities and counter misinformation;
  • Minimize social and economic impact through multisectoral partnerships.

    *This can be achieved through a combination of public health measures, such as rapid identification, diagnosis and management of the cases, identification and follow up of the contacts, infection prevention and control in healthcare settings, implementation of health measures for travellers, awareness- raising in the population and risk communication.

PREPAREDNESS AND RESPONSE

  • WHO has developed a protocol for the investigation of early cases (the “First Few X (FFX) Cases and contact investigation protocol for 2019-novel coronavirus (2019-nCoV) infection”). The protocol is designed to gain an early understanding of the key clinical, epidemiological and virological characteristics of the first cases of 2019- nCoV infection detected in any individual country, to inform the development and updating of public health guidance to manage cases and reduce potential spread and impact of infection.
  • WHO has been in regular and direct contact with Member States where cases have been reported. WHO is also informing other countries about the situation and providing support as requested.

    home care for patients with suspected novel

  • WHO has prepared disease commodity package that includes an essential list of biomedical equipment, medicines and supplies necessary to care for patients with 2019-nCoV.
  • WHO has provided recommendations to reduce risk of transmission from animals to humans.
  • WHO has published an updated advice for international traffic in relation to the outbreak of the novel

WHO has developed interim guidance for laboratory diagnosis, advice on the use of masks during home care and

in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak, clinical management,

infection prevention and control in health care settings,

risk communication and community engagement and Global Surveillance for human infection with

novel coronavirus (2019-nCoV).

coronavirus,

coronavirus 2019-nCoV.

WHO has activated of R&D blueprint to accelerate diagnostics, vaccines, and therapeutics.

WHO has developed an online course to provide general introduction to emerging respiratory viruses, including

novel coronaviruses.

• WHO is providing guidance on early investigations, which are critical to carry out early in an outbreak of a new virus. The data collected from the protocols can be used to refine recommendations for surveillance and case definitions, to characterize the key epidemiological transmission features of 2019-nCoV, help understand spread, severity, spectrum of disease, impact on the community and to inform operational models for implementation of countermeasures such as case isolation, contact tracing and isolation. Several protocols are available here: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations

• WHO is working with its networks of researchers and other experts to coordinate global work on surveillance, epidemiology, modelling, diagnostics, clinical care and treatment, and other ways to identify, manage the disease and limit onward transmission. WHO has issued interim guidance for countries, which are updated regularly.

RECOMMENDATIONS AND ADVICE FOR THE PUBLIC

WHO is working with global expert networks and partnerships for laboratory, infection prevention and control,

clinical management and mathematical modelling.

During previous outbreaks due to other coronavirus (Middle-East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), human-to-human transmission occurred through droplets, contact and fomites, suggesting that the transmission mode of the 2019-nCoV can be similar. The basic principles to reduce

the general risk of transmission of acute respiratory infections include the following:

  • Avoiding close contact with people suffering from acute respiratory infections.
  • Frequent hand-washing, especially after direct contact with ill people or their environment.
  • Avoiding unprotected contact with farm or wild animals.
  • People with symptoms of acute respiratory infection should practice cough etiquette (maintain distance, cover

    coughs and sneezes with disposable tissues or clothing, and wash hands).

  • Within healthcare facilities, enhance standard infection prevention and control practices in hospitals, especially in

    emergency departments.

WHO does not recommend any specific health measures for travellers. In case of symptoms suggestive of respiratory illness either during or after travel, travellers are encouraged to seek medical attention and share their travel history with their healthcare provider.

1 Comment

1 Comment

  1. Samuel Hay

    February 11, 2020 at 10:03 am

    January 22, 2020

    From: Samuel Hay
    PREVENTION AND CURE FOR CORONA VIRUS
    Re: I HAD SARS

    As an ardent researcher in many different fields some discoveries over the years have purposely been hidden away to protect Big Pharma’s massive profits. Some of these discoveries, it utilized could, in addition to healing and creating an atmosphere of less suffering for millions of people worldwide, save our own Medicare and Medicaid programs.
    Getting right to it, first of all there is a solution called ‘silver colloid’ which quite simply is microscopic silver particles in water. The brand I used to cure my killer staph infection which had me in bed for three months, dying, only took ten days to completely cure. Living is a wetland area I later cured myself of Lyme Disease in two weeks using the same silver colloid. I can only recommend Mesosilver as my personal experience was with this particular brand.
    About forty years ago I discovered the properties of ozone in relation to fighting communicable disease. I had to build my own ozone machine. It and its replacements have run 24/7 for all this time. Although Big Pharma has most likely been the culprit in having the FDA issue a warning, Im 77 years old and healthy as a mule. No communicable disease in this household. When they first came on the market they were priced around $650.00 but today with mass production the average cost is around $100.00 and even less for smaller models which could be used in public bathrooms to eliminate all, I said “All” disease germs. Instantly kills the AIDS virus on contact for example and it would take at least 20 minutes in pure Clorox! Ozone will permeate every inch of homes/office.
    The ozone produced in the machine is a very small amount especially compared with a lightning storm. That lightning is what cleanses the atmosphere. Have you ever seen a sign that said, “Do not breathe while near a thunderstorm?” I don’t think so. Without a positive mentality to cure not just treat contagious disease, no clinical tests will ever be performed. If you were dying from a contagious repertory disease, would you want to give it a go? I absolutely would!
    Germs cannot, as with the silver, ever become immune and the Chinese are currently fearing a mutation of the germs creating a public health emergency there.
    In layman’s terms, the microscopic silver particles in water do not work the same way as antibiotics. When the bacteria or virus uses it to hydrate, it cuts their guts apart.
    The ozone produced by the machines is O3 allowing a very unstable electron to be pulled into the outer ring but is very unstable. When it comes in contact with other atoms it can be pulled away. In the event such nearby atoms are bacteria or virus, the germs are electrocuted on a microscopic scale.
    The essence of this exercise is to make public the potential of these two discoveries as preventative and curative properties. When I go out in large crowds I spray my throat and nostrils with the silver colloids in water. Simple as that. You can take the silver internally and also apply it externally to wounds.

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top